Task Optimizing the combination of intranasal scopolamine and sensory augmentation to mitigate G-transition induced motion sickness and enhance sensorimotor performance (Wood)
Last Published:  03/26/21 03:34:00 PM (Central)
Short Title: INSCOP & Sensory Augment CMs - Lab
Responsible HRP Element: Human Health Countermeasures
Collaborating Org(s):
Funding Status: Active - Currently funded and in progress
Procurement Mechanism(s):
Solicited
Aims:
Evaluate combining intranasal scopolamine and sensory augmentation as an integrated countermeasure intended to mitigate motion sickness and enhance crew performance.

Compare motion sickness symptom severity and recovery for intranasal scopolamine (0.4 mg) and placebo control that subjects self-administer during the simulated capsule wave motion following symptom onset.

Conduct an operational clinical field study in which flight surgeons will administer intranasal scopolamine to astronauts and/or recovery operations personnel during SpaceX landings or Orion splashdown recovery simulations.
Mappings
RiskRisk of Impaired Control of Spacecraft/Associated Systems and Decreased Mobility Due to Vestibular/Sensorimotor Alterations Associated with Spaceflight
You are here!TaskOptimizing the combination of intranasal scopolamine and sensory augmentation to mitigate G-transition induced motion sickness and enhance sensorimotor performance (Wood)